Robert N Glidewell1, Brenna N Renn2, Emily Roby3, William C Orr4. 1. Lynn Institute for Healthcare Research, Colorado Springs, CO, USA. Electronic address: robert@sleeplivework.com. 2. University of Colorado, Colorado Springs, CO, USA. 3. Lynn Institute for Healthcare Research, Colorado Springs, CO, USA. 4. Lynn Institute for Healthcare Research, Oklahoma City, OK, USA; University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Lynn Institute for Healthcare Research, Colorado Springs, CO, USA.
Abstract
OBJECTIVE: Identify factors that predict improvement versus persistence of insomnia symptoms following treatment of obstructive sleep apnea (OSA) with positive airway pressure (PAP) therapy. METHODS: Archival data from 68 PAP-treated sleep apnea patients aged 25-83 were analyzed using nonparametric tests and stepwise regression to assess the relationships between insomnia symptoms, multiple OSA variables, and PAP use over time. RESULTS: Pretreatment insomnia symptom severity (ISS; b = -0.72, p < 0.001), PAP average use (b = -0.01, p = 0.01) and respiratory disturbance index (RDI; b = -0.02, p = 0.03) predict change in insomnia following PAP therapy. Forty-five percent (24/53) of the subjects with moderate to severe insomnia at pretreatment reported no/mild symptoms after PAP therapy and were considered improved. Improved subjects had lower pretreatment ISS (p < 0.001), higher RDI (p = 0.01), and higher average PAP use (p < 0.035) than subjects with persistent insomnia. Number of medications and comorbidities were similar between improved and persistent groups. New onset of insomnia symptoms occurred in 13% (2/15) of the patients with no/mild pretreatment insomnia. CONCLUSIONS: Although ISS declines following PAP treatment, 55% of OSA patients have persistent moderate to severe symptoms despite treatment. More severe OSA is linked to higher likelihood of insomnia improvement and the effect of PAP therapy on insomnia may be mediated by OSA severity. Persistent insomnia is unrelated to medication use or comorbidities and may represent an independent, self-sustaining disorder requiring targeted intervention.
OBJECTIVE: Identify factors that predict improvement versus persistence of insomnia symptoms following treatment of obstructive sleep apnea (OSA) with positive airway pressure (PAP) therapy. METHODS: Archival data from 68 PAP-treated sleep apneapatients aged 25-83 were analyzed using nonparametric tests and stepwise regression to assess the relationships between insomnia symptoms, multiple OSA variables, and PAP use over time. RESULTS: Pretreatment insomnia symptom severity (ISS; b = -0.72, p < 0.001), PAP average use (b = -0.01, p = 0.01) and respiratory disturbance index (RDI; b = -0.02, p = 0.03) predict change in insomnia following PAP therapy. Forty-five percent (24/53) of the subjects with moderate to severe insomnia at pretreatment reported no/mild symptoms after PAP therapy and were considered improved. Improved subjects had lower pretreatment ISS (p < 0.001), higher RDI (p = 0.01), and higher average PAP use (p < 0.035) than subjects with persistent insomnia. Number of medications and comorbidities were similar between improved and persistent groups. New onset of insomnia symptoms occurred in 13% (2/15) of the patients with no/mild pretreatment insomnia. CONCLUSIONS: Although ISS declines following PAP treatment, 55% of OSA patients have persistent moderate to severe symptoms despite treatment. More severe OSA is linked to higher likelihood of insomnia improvement and the effect of PAP therapy on insomnia may be mediated by OSA severity. Persistent insomnia is unrelated to medication use or comorbidities and may represent an independent, self-sustaining disorder requiring targeted intervention.
Keywords:
Apnea–hypopnea index (AHI); Comorbidity; Insomnia; Insomnia Severity Index (ISI); Positive air pressure (PAP); Respiratory disturbance index (RDI); Sleep apnea
Authors: Yong Won Cho; Keun Tae Kim; Hye-Jin Moon; Valeriy R Korostyshevskiy; Gholam K Motamedi; Kwang Ik Yang Journal: J Clin Sleep Med Date: 2018-03-15 Impact factor: 4.062
Authors: Alexander Sweetman; Bastien Lechat; Peter G Catcheside; Simon Smith; Nick A Antic; Amanda O'Grady; Nicola Dunn; R Doug McEvoy; Leon Lack Journal: Front Psychol Date: 2021-05-04
Authors: David J McIver; Jared B Hawkins; Rumi Chunara; Arnaub K Chatterjee; Aman Bhandari; Timothy P Fitzgerald; Sachin H Jain; John S Brownstein Journal: J Med Internet Res Date: 2015-06-08 Impact factor: 5.428